Pharmaceuticals will continue to see steady growth led by higher sales from Imbruvica and Darzalex. The halt in elective procedures like hip replacements could take a bite out of its devices sales, and it's committed to sink hundreds of millions into a potential vaccine that may never come to fruition—but, if successful, could help the company's top line and play a role in getting the rest of the world back to business. ", Johnson & Johnson, Johnson & Johnson's total sales from 2005 to 2019 (in million U.S. dollars) Statista, https://www.statista.com/statistics/266403/total-revenue-of-johnson-und-johnson-since-2004/ (last visited October 16, 2020), We use cookies to personalize contents and ads, offer social media features, and analyze access to our website. "Johnson & Johnson's Total Sales from 2005 to 2019 (in Million U.S. See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams, Led by MIT engineers and Wall Street analysts, Trefis (through its dashboards platform dashboards.trefis.com) helps you understand how a company's products, that you. Get the detailed quarterly/annual income statement for Johnson & Johnson (JNJ). Johnson & Johnson (NYSE: JNJ) will release its Q4 and full-year 2019 results on Wednesday, January 22, and it will likely beat the consensus earnings by $0.02, in our view. Sales of Stelara, also used to treat psoriasis, rose 33.6 percent to $1.44 billion. and over 1 Mio. The company is headquartered in New Brunswick, New Jersey. pharmaceutical company Johnson & Johnson at the entrance of the research and development plant, in Val-de-Reuil, northwestern France. The largest drug company worldwide by overall sales, Johnson & Johnson is a global healthcare behemoth spanning pharmaceuticals, consumer healthcare and medical devices. Surprisingly, the founders of Trefis discovered that along with most other people they just did not understand even the seemingly familiar companies around them: Apple, Google, Coca Cola, Walmart, GE, Ford, Gap, and others. Total revenues have increased at an average annual rate of 6.5% from $71.9 billion in 2016 to $81.6 billion in 2018. Expect more generic erosion this year, too: When executives reported their full-year results for 2019, they warned pharma watchers that 2020 wouldn't be exempt from that trend. Johnson & Johnson's total sales from 2005 to 2019 (in million U.S. dollars) [Graph]. Trefis forecast for Johnson & Johnson’s 2019 earnings, as well as P/E multiple, are slightly higher than the market expectations, working out to a fair value of $161 for Johnson & Johnson’s stock, which is roughly 8% higher than the current market price of around $149. Johnson & Johnson net income for the twelve months ending June 30, 2020 was $15.185B, a 7.02% decline year-over-year. The platform uses extensive data to show in a single snapshot what drives the value of a company's business. See here for a complete list of exchanges and delays. Excluding items, the company earned $1.97 per share, beating analysts' average estimate of $1.95 per share. Of course, within J&J's pharma group, there were standouts and laggards. The company’s prostate cancer drug Zytiga, an important growth driver, is expected to be pressured by generic competition, while sales of its rheumatoid arthritis drug Remicade has been slipping due to competition from cheaper biosimilar versions. New Brunswick, N.J. (January 22, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2019. J&J has repeatedly defended the safety of its talc products, saying that decades of studies have shown them be asbestos-free and that they do not cause cancer. For 2020, we believe that slightly lower growth in expenses, and no changes in revenue, will result in the net income margin figure to see a modest decline to 28.3%. Johnson’s 133rd year was extraordinary. Johnson & Johnson annual revenue for 2019 was $82.059B, a 0.59% increase from 2018. Chart. Notably, Johnson & Johnson’s revenue will likely hover around the $82-billion mark over 2019-2020, as the company faces competition for its blockbuster drugs Remicade and Zytiga following the end of their market exclusivity period. Reuters on Dec. 14 published a special report detailing that the company knew for decades that cancer-causing asbestos could be found in the product. Use a + to require a term in results and - to The company said it expects full-year sales in the range of $80.4 billion (£62 billion) to $81.2 billion, compared with the average analyst estimate of $82.69 billion, according to IBES data from Refinitiv. / AFP PHOTO / CHARLY TRIBALLEAU (Photo credit should read CHARLY TRIBALLEAU/AFP via Getty Images). J&J and other drug companies haven't yet finalized their opioid settlements. The company posted net profit of $3.04 billion, or $1.12 per share, for the fourth quarter, compared with a loss of $10.71 billion, or $3.99 per share, a year earlier, when it recorded a $13.6 billion charge related to changes to the U.S. tax law.